LAUSR

Imatinib (IMA) Low Dose Reduction Program (LDR) in Chronic Myeloid Leukemia Ph+ (CML Ph+) in a Single Reference Institution in Mexico City. Ongoing Preliminary Results

Sign Up to like & get
recommendations!
1 Published in 2019 at "Blood"

DOI: 10.1182/blood-2019-130873

Abstract: Imatinib (IMA) total stop therapy has interesting worldwide results in selected patients (pts) with CML Ph+ who have achieved 4 to 5 log reduction of BCR/ABL copies, however there is no information of LDR. The… read more here.

Keywords: reduction; cml; imatinib ima; program ... See more keywords